

Kei Muro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5063719/publications.pdf>

Version: 2024-02-01

74
papers

13,543
citations

136885

32
h-index

85498

71
g-index

74
all docs

74
docs citations

74
times ranked

11917
citing authors

#	ARTICLE	IF	CITATIONS
1	Second-line pembrolizumab versus chemotherapy in Japanese patients with advanced esophageal cancer: subgroup analysis from KEYNOTE-181. <i>Esophagus</i> , 2022, 19, 137-145.	1.0	8
2	Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial. <i>Gastric Cancer</i> , 2022, 25, 197-206.	2.7	72
3	Effect of Body Composition Change during Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma. <i>Journal of Clinical Medicine</i> , 2022, 11, 508.	1.0	5
4	The survival benefit of increasing the number of active drugs for metastatic colorectal cancer: A multicenter retrospective study. <i>Cancer Medicine</i> , 2022, , .	1.3	2
5	A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in patients with cancer cachexia and low body mass index. <i>Cancer</i> , 2022, 128, 2025-2035.	2.0	18
6	Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 3686-3694.	3.2	1
7	Second-line chemotherapy using taxane in patients with advanced gastric cancer who presented with severe peritoneal metastasis: a multicenter retrospective study. <i>International Journal of Clinical Oncology</i> , 2021, 26, 355-363.	1.0	5
8	Tumor Response and Symptom Palliation from RAINBOW , a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer. <i>Oncologist</i> , 2021, 26, e414-e424.	1.9	4
9	Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10. <i>Clinical Cancer Research</i> , 2021, 27, 1923-1931.	3.2	53
10	An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT). <i>TJ ETQq0 0 0 rgB.7/Overlock 10 Tf 50</i>	1.1	1
11	An observational study on nutrition status in gastric cancer patients receiving ramucirumab plus taxane: BALAST study. <i>Future Oncology</i> , 2021, 17, 2431-2438.	1.1	1
12	Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061. <i>Gastric Cancer</i> , 2021, 24, 1330-1340.	2.7	7
13	Clinical implications of using both fluoropyrimidine and paclitaxel in patients with severe peritoneal metastasis of gastric cancer: A post hoc study of JCOG1108/WJOG7312G. <i>Cancer Medicine</i> , 2021, 10, 7673-7682.	1.3	2
14	Quality of Life Associated with Ramucirumab Treatment in Patients with Advanced Gastric Cancer in Japan: Exploratory Analysis from the Phase III RAINBOW Trial. <i>Clinical Drug Investigation</i> , 2021, 41, 53-64.	1.1	1
15	Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1-42.	1.0	1,123
16	Pertuzumab plus trastuzumab and chemotherapy for Japanese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subgroup analysis of the JACOB trial. <i>International Journal of Clinical Oncology</i> , 2020, 25, 301-311.	1.0	8
17	Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 4138-4148.	0.8	614
18	Prognostic Impact of Sarcopenic Obesity after Neoadjuvant Chemotherapy Followed by Surgery in Elderly Patients with Esophageal Squamous Cell Carcinoma. <i>Journal of Clinical Medicine</i> , 2020, 9, 2974.	1.0	20

#	ARTICLE	IF	CITATIONS
19	Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G). <i>European Journal of Cancer</i> , 2020, 135, 11-21.	1.3	14
20	Phase I Study of Alternate-Day Administration of S-1, Oral Leucovorin, and Bevacizumab for Refractory Metastatic Colorectal Cancer. <i>Oncologist</i> , 2020, 25, e1614-e1620.	1.9	0
21	Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G. <i>Cancers</i> , 2020, 12, 1715.	1.7	7
22	Randomized phase II/III study of 5-fluorouracil/leucovorin versus 5-fluorouracil/leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108/WJOG7312G). <i>Gastric Cancer</i> , 2020, 23, 677-688.	2.7	25
23	Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data. <i>Cancers</i> , 2020, 12, 844.	1.7	8
24	Immune checkpoint inhibitor plus anti-HER2 therapy: a new standard for HER2-positive oesophagogastric cancer?. <i>Lancet Oncology</i> , The, 2020, 21, 741-743.	5.1	2
25	Impact of sex and histology on the therapeutic effects of fluoropyrimidines and oxaliplatin plus bevacizumab for patients with metastatic colorectal cancer in the SOFT trial. <i>Global Health & Medicine</i> , 2020, 2, 240-246.	0.6	4
26	A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia. <i>Cancer</i> , 2019, 125, 4294-4302.	2.0	99
27	Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study. <i>BMC Cancer</i> , 2019, 19, 652.	1.1	15
28	Molecular alterations and PD-L1 expression in non-ampullary duodenal adenocarcinoma: Associations among clinicopathological, immunophenotypic and molecular features. <i>Scientific Reports</i> , 2019, 9, 10526.	1.6	9
29	Prognostic Significance of Sarcopenia in Patients with Unresectable Advanced Esophageal Cancer. <i>Journal of Clinical Medicine</i> , 2019, 8, 1647.	1.0	18
30	Comprehensive registry of esophageal cancer in Japan, 2012. <i>Esophagus</i> , 2019, 16, 221-245.	1.0	112
31	Systemic chemotherapy for gastric cancer with early recurrence after adjuvant S-1 monotherapy: a multicenter retrospective study. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1197-1203.	1.0	5
32	Current and Future Aspects of Immunotherapy for Esophageal and Gastric Malignancies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 237-247.	1.8	18
33	Is ramucirumab and paclitaxel therapy beneficial for second-line treatment of metastatic gastric or junctional adenocarcinoma for patients with ascites? Analysis of RAINBOW phase 3 trial data. <i>Cancer Management and Research</i> , 2019, Volume 11, 2261-2267.	0.9	4
34	Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. <i>Gastric Cancer</i> , 2019, 22, 828-837.	2.7	181
35	Observational study of first-line chemotherapy including cetuximab in patients with metastatic colorectal cancer: CORAL trial. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 339-346.	0.6	3
36	Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial. <i>Gastric Cancer</i> , 2019, 22, 817-827.	2.7	42

#	ARTICLE	IF	CITATIONS
37	Society of Internal Medicine, 2019, 108, 1777-1787.	0.0	0
38	Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012. Cancer Science, 2018, 109, 771-776.	1.7	48
39	The subgroups of the phase III RECURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. European Journal of Cancer, 2018, 90, 63-72.	1.3	69
40	Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer. JAMA Oncology, 2018, 4, e180013.	3.4	1,350
41	Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T 5 colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncology, The, 2018, 19, 660-671.	5.1	107
42	Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. International Journal of Clinical Oncology, 2018, 23, 1-34.	1.0	1,187
43	Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. British Journal of Cancer, 2018, 119, 153-159.	2.9	329
44	Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet, The, 2018, 392, 123-133.	6.3	984
45	Challenges in molecular targeted therapy for gastric cancer: considerations for efficacy and safety. Expert Opinion on Drug Safety, 2017, 16, 319-327.	1.0	11
46	Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2017, 390, 2461-2471.	6.3	1,749
47	Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer. Molecular Cancer Therapeutics, 2017, 16, 2215-2222.	1.9	41
48	Efficacy and safety of taxane monotherapy in advanced gastric cancer refractory to triplet chemotherapy with docetaxel, cisplatin, and S-1: a multicenter retrospective study. Cancer Chemotherapy and Pharmacology, 2017, 80, 575-582.	1.1	6
49	Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data. Journal of Gastric Cancer, 2017, 17, 132.	0.9	54
50	Study protocol of the Asian XELIRI Project (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab. Chinese Journal of Cancer, 2016, 35, 102.	4.9	12
51	Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer in WJOG 6210G. Cancer Science, 2016, 107, 1843-1850.	1.7	60
52	A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer. Gynecologic Oncology, 2016, 142, 62-69.	0.6	70
53	Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncology, The, 2016, 17, 717-726.	5.1	943
54	Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer. Gastric Cancer, 2016, 19, 927-938.	2.7	67

#	ARTICLE	IF	CITATIONS
55	A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 153-160.	1.2	26
56	Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802). <i>BMC Cancer</i> , 2015, 15, 176.	1.1	2
57	Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2015, 20, 207-239.	1.0	548
58	A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer. <i>BMC Cancer</i> , 2015, 15, 601.	1.1	13
59	Efficacy of palliative radiotherapy for gastric bleeding in patients with unresectable advanced gastric cancer: a retrospective cohort study. <i>BMC Palliative Care</i> , 2015, 14, 37.	0.8	63
60	The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer. <i>Future Oncology</i> , 2015, 11, 1471-1478.	1.1	6
61	Clinical Characteristics Associated with Long-term Survival in Metastatic Gastric Cancer after Systemic Chemotherapy. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 5433-5438.	0.5	6
62	Panitumumab in Japanese Patients with Unresectable Colorectal Cancer: A Post-marketing Surveillance Study of 3085 Patients. <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 214-223.	0.6	20
63	Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1224-1235.	5.1	1,932
64	Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 3935-3943.	0.8	411
65	Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 1278-1286.	5.1	227
66	Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 595-603.	1.2	5
67	TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. <i>Lancet Oncology</i> , The, 2012, 13, 993-1001.	5.1	267
68	Sensitivity to previous irinotecan treatment does not predict the efficacy of combination chemotherapy with cetuximab plus irinotecan for wild-type KRAS metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2011, 47, 2673-2680.	1.3	1
69	A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 1265-1272.	1.1	102
70	Conversion Chemotherapy Using Cetuximab plus FOLFIRI Followed by Bevacizumab plus mFOLFOX6 in Patients with Unresectable Liver Metastases from Colorectal Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 1229-1232.	0.6	10
71	Phase I/II Study of Capecitabine Plus Oxaliplatin (XELOX) Plus Bevacizumab As First-line Therapy in Japanese Patients with Metastatic Colorectal Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 913-920.	0.6	40
72	Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS) <i>Tj ETQq0 0 0 rgBT /Overlook 10 Tf 5</i>		

#	ARTICLE	IF	CITATIONS
73	A Phase 2 Clinical Trial of Panitumumab Monotherapy in Japanese Patients with Metastatic Colorectal Cancer. Japanese Journal of Clinical Oncology, 2009, 39, 321-326.	0.6	54
74	Chemotherapy for patients with advanced gastric cancer with performance status 2. Gastrointestinal Cancer Research: GCR, 2009, 3, 220-4.	0.8	7